These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26040217)

  • 1. Besifloxacin in the management of bacterial infections of the ocular surface.
    Deschênes J; Blondeau J
    Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections.
    Nguyen AT; Hong AR; Baqai J; Lubniewski AJ; Huang AJ
    Cornea; 2015 Aug; 34(8):967-71. PubMed ID: 26075451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP
    Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS; Zhang JZ
    Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
    Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
    Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
    DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM
    PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL; Paterno MR; Usner DW; Pichichero ME
    Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
    Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
    Nafziger AN; Bertino JS
    Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of besifloxacin in the treatment of bacterial conjunctivitis.
    Mahvan TD; Hornecker JR; Buckley WA; Clark S
    Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
    Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
    Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Besifloxacin ophthalmic suspension 0.6%.
    Carter NJ; Scott LJ
    Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
    Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
    Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
    Miller D; Chang JS; Flynn HW; Alfonso EC
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
    Sanders ME; Moore QC; Norcross EW; Shafiee A; Marquart ME
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
    Sanfilippo CM; Allaire CM; DeCory HH
    Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
    Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.